Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoanthraquinone hydrochloride liposomes + azacitidine + venetoclax for newly treated AML
ChiCTR2400093555Phase 4Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone hydrochloride, azacitidine and venetoclax in acute myeloid leukemia (AML), sponsored by Tangdu Hospital. Primary endpoint: Compound remission rate after treatment. Started Dec 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochlorideazacitidinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400093555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093555.